Clinical pharmacist interventions in managing drug-related problems in hospitalized patients with neurological diseases
Background Drug-related problems (DRPs) are common in hospitalized patients with neurological diseases. Clinical pharmacy services could minimize drug-related harm and improve patient care. Objective To identify common DRPs in neurology and document clinical pharmacists’ medication-related interventions. Setting The wards and intensive care unit of the Department of Neurology at Assiut University Hospital. Method Prospective study of clinical pharmacists’ interventions during the routine care work of reviewing patients medical charts over a period of 6 months from January to June 2017. Main outcome measure The frequency and severity of DRPs and clinical pharmacists’ recommendations. Results Out of 1421 reviewed medications charts, a total of 414 DRPs were detected for 285 admitted patients. The most common DRPs were drug selection problems (36.7%) and dosing errors (27.5%). The majority of DRPs (71.7%) were categorized as causing no patient harm. Clinical pharmacists provided recommendations for the detected problems that ranged from drug monitoring to stop and starting new medicines. About 90% of pharmacists’ interventions were accepted by physicians. Poisson regression of factors that may influence the frequency of DRPs revealed significant associations of patient age (p = 0.03) and the number of comorbid diseases (p = 0.01). Conclusions Prescribing errors in neurology inpatient are likely to occur. Clinical pharmacists’ interventions assisted in early detection of drug problems and prevention of the consequent patient harms.
KeywordsClinical pharmacists Drug-related problems Egypt Hospitalized patients Neurology Patient harm
Assistance of pharmacists, Asmaa Alhosainy and Eman Mostafa in data collection and documentation of drug-related problems for this study, is gratefully acknowledged.
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Conflicts of interest
The authors declare no conflict of interest.
- 1.World Health Organization. World alliance for patient safety. Geneva: WHO; 2005. http://www.who.int/patientsafety/en/brochure_final.pdf Accessed 9 Sept 2017.
- 13.Pharmaceutical Care Network Europe drug-related problem classification (PCNE-DRP). 2017 June 2017. http://www.pcne.org/upload/files/11_PCNE_classification_V6-2.pdf. Accessed Jan 2017.
- 14.Lexicomp—clinical drug information. https://online.lexi.com/lco/action/login. Accessed 20 Feb 2017.
- 17.European Stroke Organization (ESO) guidelines. https://eso-stroke.org/eso-guideline-directory/. Accessed 02 Jan 2017.
- 18.National Institute for Health and Clinical excellence: guidance. In: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care: pharmacological update of clinical guideline 20. London: Royal College of Physicians (UK), National Clinical Guideline Centre; 2012. p. 1–99Google Scholar
- 19.The national coordinating council for medication error reporting and prevention (NCC MERP) index. 2001 June 2017. http://www.nccmerp.org/types-medication-errors. Accessed Jan 2017.
- 20.Dornan T, Ashcroft D, Heathfield H, Lewis P, Miles J, Taylor D, et al. An in depth investigation into causes of prescribing errors by foundation trainees in relation to their medical education. EQUIP Study. London: General Medical Council; 2009.Google Scholar